Chapter 172
“No need.” Dallas turned on the tap.
Ryan waited anxiously at the door.
It wasn’t until the water stopped running that Ryan heard Dallas moving the stool. He knocked on the door again. “Can I come in?”
“Please come in.”
Ryan opened the door and saw the little boy dripping wet, wrapped in a bear–themed towel.
He looked as cute as a baby bear himself with the bear hat on his head, but his face still had a touch of
coolness.
“Is there anything you need?” Dallas asked.
“It’s a little dangerous for children to use a hairdryer. Let me help you dry your hair.” Ryan plugged in the hairdryer and removed Dallas‘ hat to blow dry his hair.
He glanced up into the mirror, observing Ryan as he blow–dried his hair, the older man’s hands delicately tousling his locks.
It felt… comfortable.
After drying his hair and brushing his teeth, Dallas headed out with his pajamas in hand. “I’ll go change. You hurry up and take a shower!”
“Alright.” Ryan smiled as he watched Dallas‘ retreating figure.
By the time Ryan finished showering and came out, Dallas had already fallen asleep.
Dallas looked exactly like Lily when he was asleep, except Dallas‘ eyebrows were slightly thicker.
Although both kids were as delicate as dolls, you could still tell that Dallas was a little boy.
Ryan kissed Dallas‘ chubby cheek and tucked him in. He then lay beside him, carefully embracing him
as he did with Lily.
In Ryan’s eyes, Dallas and Lily were his treasures.
On the 29th, the Evergreen Biotech hearing took place in Meplaria. This was led by Derek Cooper, who
oversaw the company’s operations in Eurindel and Meplaria.
The hearing was broadcast worldwide.
Audrey stood before her juicer, watching Derek on the TV screen. She sipped the fruit and vegetable juice, not paying too much attention to the hearing.
However, the news in Meplaria had already exploded.
Chapter 122
2/2
People spontaneously organized demonstrations outside the Meplaria Congress building, rallying to support Evergreen Biotech.
The reason was simple: Evergreen Biotech’s technology had saved many lives.
Audrey had been slowly releasing news half a month ago.
News outlets published that if Evergreen Biotech did not receive a fair trial in Meplaria, they would completely withdraw from the local market, terminating all collaborations with major universities and hospitals–even at the cost of paying hefty breach–of–contract penalties.
This matter concerned everyone’s life, so the public wouldn’t sit idly by. After all, who could guarantee that they wouldn’t suffer from a terminal illness in their lifetime?
Currently, only Evergreen Biotech had drug formulas to treat cancer and Alzheimer’s disease. Even drugs that could control ALS were in clinical trials.
If Evergreen Biotech left the Meplaria market, what would happen if people got sick and didn’t have medicine?
Perhaps they would eventually develop new drugs, but who could guarantee they wouldn’t fall ill before the new drugs were developed?
These people supported Evergreen Biotech not just to show solidarity, but also to give themselves some hope.
